Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Recordati SpAMEX:RECN 72 Pretax Margin % is 23.11% as of Jun. 2026, which is 19% below its 10-year median of 28.41. GuruFocus rates MEX:RECN with a GF Score™ of 72/100 and a GF Value™ of MXN1,202.90 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 959 Drug Manufacturers companies, Recordati SpA ranks better than 86.76% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Recordati SpA's Pre-Tax Income for the
three
months ended in Jun. 2026 was MXN3,240 Mil. Recordati SpA's Revenue for the
three
months ended in Jun. 2026 was MXN14,019 Mil. Therefore, Recordati SpA's pretax margin for the quarter that ended in Jun. 2026 was 23.11%.
The historical rank and industry rank for Recordati SpA's Pretax Margin % or its related term are showing as below:
MEX:RECN'
s Pretax Margin % Range Over the Past 10 Years
Min: 21.66 Med: 28.41 Max: 31.45
Current: 24.35
MEX:RECN's Pretax Margin % is ranked better than 86.76% of 959
companies
in the Drug Manufacturers industry
Industry Median: 7.03
vs MEX:RECN: 24.35
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Recordati SpA Pretax Margin % Related Terms
Recordati SpA Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Recordati SpA's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:RECN vs LLY, JNJ, ABBV: Pretax Margin % Comparison
For the Drug Manufacturers - General subindustry, Recordati SpA's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Recordati SpA Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Recordati SpA's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Recordati SpA's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Recordati SpA (MEX:RECN) has a Pretax Margin % of 23.11% as of Jun. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Recordati SpA and its competitors. This is 19% below median its historical median of 28.41. Over the past decade, Recordati SpA's Pretax Margin % has ranged from 21.66 to 31.45. According to the industry distribution chart, Recordati SpA ranks #127 out of 959 companies in the Drug Manufacturers industry, placing it in the top 13.2%.
Is Recordati SpA's Pretax Margin % too high?
Recordati SpA's current Pretax Margin % of 23.11% is 19% below median its 10-year median of 28.41. Over the past 10 years, this metric has ranged from a low of 21.66 to a high of 31.45. The Drug Manufacturers industry median Pretax Margin % is 7.03. Recordati SpA's value of 23.11% is 228.7% above this industry median. Based on the distribution chart, Recordati SpA ranks #127 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Recordati SpA has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Recordati SpA's Pretax Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Recordati SpA ranks #127 out of 959 companies for Pretax Margin %. This places Recordati SpA in the top 13% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 7.03. Recordati SpA's value of 23.11% is 228.7% above this benchmark. Historically, Recordati SpA's own Pretax Margin % has ranged from 21.66 to 31.45 over the past decade. While the company's 10-year median is 28.41 vs. the industry median of 7.03, Recordati SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.03, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Recordati SpA's current Pretax Margin % of 23.11% is 228.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Recordati SpA and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Recordati SpA's current Pretax Margin % is 23.11%, which is 19% below median its own 10-year median of 28.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recordati SpA stock overvalued right now?
Based on GuruFocus' analysis, Recordati SpA (MEX:RECN) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN1,202.90, compared to a current price of MXN1,019.79 — trading 15.2% below its estimated fair value. The current Pretax Margin % is 23.11%, which is 19% below median its 10-year median of 28.41 and 228.7% above the Drug Manufacturers industry median of 7.03. Recordati SpA's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Recordati SpA (MEX:RECN), the current Pretax Margin % is 23.11% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Recordati SpA (MEX:RECN) Overvalued in 2026?
Based on GuruFocus' analysis, Recordati SpA stock appears to be undervalued.
The current stock price of MXN1,019.79 is trading 15.2% below its estimated GF Value™ of MXN1,202.90.
GuruFocus considers Recordati SpA to be Modestly Undervalued.
Key valuation signals for MEX:RECN:
Pretax Margin %: 23.11% (19% below median its 10-year median of 28.41)
GF Value™: MXN1,202.90 vs. price of MXN1,019.79 (15.2% below fair value)
Industry Position: 228.7% above the Drug Manufacturers median (#127 of 959)
No single metric tells the full story. See the MEX:RECN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Recordati SpA is engaged in the development, production, and marketing of pharmaceutical products or of pharmaceutical chemicals. The Company operates in a broad and diverse context, which includes general medicine, specialist medicine, self-medication, and rare diseases. In addition, it is also active in the field of urology, with treatments for benign prostatic hyperplasia and male functional disorders, and in psychiatry. The Company's only operating segment is the Specialty & Primary Care segment. Its geographic areas are Europe, Australasia, America, and Africa.
72GF Score
Get the complete analysis for MEX:RECN
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RECN has been successfully added to your 
